SLC5A2 and metabolic syndrome: After consolidating these pre-clinical findings and concluding that the SGLT2 inhibition may result in sympathoinhibition, our group is now conducting a clinical trial to determine whether EMPA also exerts direct sympathoinhibitory effects on the heart and kidneys in human subjects with the MetS.